Welcome a special ASGCT Annual Meeting preview hosted by Lynnea Olivarez, member of the ASGCT Communications Committee.

Today's guest is Emily Mullin, a staff writer at WIRED who covers biotechnology, medicine, and genetics. Emily is a stalwart on the CGT beat, and today, we're looking ahead to the major topics and themes that will be highlighted at the upcoming ASGCT Annual Meeting.

The ASGCT Annual Meeting is the field's flagship event, bringing together stakeholders from academia, industry, regulatory agencies, and more. It's a prime opportunity to exchange research, trends, and the latest in the field.

Registration is now open and we hope you'll join us in Baltimore, May 7-11.

Find Emily Mullin's work at WIRED.com: https://www.wired.com/author/emily-mullin/

Register today for the ASGCT Annual Meeting: https://annualmeeting.asgct.org/

'Felicity' by Scott Buckley - released under CC-BY 4.0.
www.scottbuckley.com.au

Welcome a special <a href="https://annualmeeting.asgct.org/">ASGCT Annual Meeting</a> preview hosted by Lynnea Olivarez, member of the ASGCT Communications Committee.
Today's guest is <a href="https://www.wired.com/author/emily-mullin/">Emily Mullin, a staff writer at WIRED</a> who covers biotechnology, medicine, and genetics. Emily is a stalwart on the CGT beat, and today, we're looking ahead to the major topics and themes that will be highlighted at the upcoming <a href="https://annualmeeting.asgct.org/">ASGCT Annual Meeting</a>.
The <a href="https://annualmeeting.asgct.org/">ASGCT Annual Meeting</a> is the field's flagship event, bringing together stakeholders from academia, industry, regulatory agencies, and more. It's a prime opportunity to exchange research, trends, and the latest in the field.
Registration is now open and we hope you'll join us in Baltimore, May 7-11.
Find Emily Mullin's work at WIRED.com: <a href="https://www.wired.com/author/emily-mullin/">https://www.wired.com/author/emily-mullin/</a>
Register today for the ASGCT Annual Meeting: <a href="https://annualmeeting.asgct.org/">https://annualmeeting.asgct.org/</a>
'Felicity' by Scott Buckley - released under CC-BY 4.0. <a href="https://url.us.m.mimecastprotect.com/s/3E0CC684xnU7PqyI65U9e">www.scottbuckley.com.au</a>

The American Society of Gene & Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

The American Society of Gene &amp; Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

ASGCT Podcast Network

Hot Topics in CGT with WIRED's Emily Mullin: Annual Meeting Preview

Host Emily Walsh Martin, PhD, is joined by Chris Choi, PhD, Roswell Park Comprehensive Cancer Center's Senior Vice President of Industry Partnerships and Technical Director of the center’s new Good Manufacturing Practice (cGMP) Facility. Dr. Choi is also an associate professor of oncology. This wide-ranging conversation covers cell therapy development and manufacturing and how the growing Roswell Park Center is aiming to support sponsors in the CAR T and cell therapy space. Emily and Chris also discuss their experiences on cross-functional teams and how a program's research, manufacturing, and clinical elements must be knit together for success.

Music by: https://www.steven-obrien.net/
--------------------------
Bright New Morning - Steven O'Brien

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Host Emily Walsh Martin, PhD, is joined by Chris Choi, PhD, Roswell Park Comprehensive Cancer Center's Senior Vice President of Industry Partnerships and Technical Director of the center’s new Good Manufacturing Practice (cGMP) Facility. Dr. Choi is also an associate professor of oncology. This wide-ranging conversation covers cell therapy development and manufacturing and how the growing Roswell Park Center is aiming to support sponsors in the CAR T and cell therapy space. Emily and Chris also discuss their experiences on cross-functional teams and how a program's research, manufacturing, and clinical elements must be knit together for success.
Music by: <a href="https://protect-us.mimecast.com/s/2tr6CrknqPT6KWqS7Xin0">https://www.steven-obrien.net/</a> -------------------------- Bright New Morning - Steven O'Brien
(Used for free under a Creative Commons Attribution 4.0 License: <a href="https://protect-us.mimecast.com/s/FOoyCv2rxWt4mR9fX52Pt">https://creativecommons.org/licenses/by/4.0/</a>)

cGMP and Building Cohesive Teams with Christopher Choi, PhD, Roswell Park Comprehensive Cancer Center - The Issue

This episode features a conversation between Dr. Roland Herzog and Dr. Joseph Glorioso. On January 1, 2025, Dr. Glorioso will begin his 5-year term as the Editor-in-Chief of Molecular Therapy, marking the end of Dr. Herzog’s successful tenure at the helm of the journal. Drs.Herzog and Glorioso engage in a wide-ranging conversation that touches on the history of Molecular Therapy, highlights from the gene and cell therapy field, and how Molecular Therapy will continue to grow and evolve under Dr. Glorioso’s leadership.

ASGCT is proud to present this episode of the Molecular Therapy Podcast in partnership with our upcoming Breakthroughs in Muscular Dystrophy conference on November 19th and 20th in Chicago, and virtually This event will provide an unparalleled opportunity to delve into the latest advancements in research on gene and cell therapies for muscular dystrophy. Learn more and register today at ASGCT.org/Breakthroughs.

In This Episode:

Dr. Roland Herzog
Editor-in-Chief of Molecular Therapy and Professor of Pediatrics, Riley Children's Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program at Indiana University

Dr. Joseph Glorioso
Professor, Department of Microbiology and Molecular Genetics and Department of Human Genetics at the University of Pittsburgh


'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.
www.scottbuckley.com.au

This episode features a conversation between Dr. Roland Herzog and Dr. Joseph Glorioso. On January 1, 2025, Dr. Glorioso will begin his 5-year term as the Editor-in-Chief of Molecular Therapy, marking the end of Dr. Herzog’s successful tenure at the helm of the journal. Drs.Herzog and Glorioso engage in a wide-ranging conversation that touches on the history of Molecular Therapy, highlights from the gene and cell therapy field, and how Molecular Therapy will continue to grow and evolve under Dr. Glorioso’s leadership.
ASGCT is proud to present this episode of the Molecular Therapy Podcast in partnership with our upcoming Breakthroughs in Muscular Dystrophy conference on November 19th and 20th in Chicago, and virtually This event will provide an unparalleled opportunity to delve into the latest advancements in research on gene and cell therapies for muscular dystrophy. Learn more and register today at <a href="ASGCT.org/Breakthroughs">ASGCT.org/Breakthroughs.</a>
In This Episode:
Dr. Roland Herzog Editor-in-Chief of Molecular Therapy and Professor of Pediatrics, Riley Children's Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program at Indiana University
Dr. Joseph Glorioso Professor, Department of Microbiology and Molecular Genetics and Department of Human Genetics at the University of Pittsburgh 
'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. <a href="https://protect-us.mimecast.com/s/CXOTCL9w1QUXqP0HBBFDP">www.scottbuckley.com.au</a>

A New Era of Molecular Therapy with Joseph Glorioso, PhD

Derek Jackson, vice president of cell and gene therapy product development at Pacira BioSciences, joins The Issue to take the program in a different direction.

We often focus our discussions on CGT for rare diseases. Most of the time, the teams of scientists working on the program don’t have any personal experience with the disease from their family, friends, or themselves.. but today we will talk about gene therapy development for a much more common disease: knee osteoarthritis. Moreover, the product we will be discussing is not only non-rare but also non-AAV. 

Music by: https://www.steven-obrien.net/
--------------------------
Bright New Morning - Steven O'Brien

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Derek Jackson, vice president of cell and gene therapy product development at Pacira BioSciences, joins The Issue to take the program in a different direction.
We often focus our discussions on CGT for rare diseases. Most of the time, the teams of scientists working on the program don’t have any personal experience with the disease from their family, friends, or themselves.. but today we will talk about gene therapy development for a much more common disease: knee osteoarthritis. Moreover, the product we will be discussing is not only non-rare but also non-AAV. 
Music by: <a href="https://protect-us.mimecast.com/s/2tr6CrknqPT6KWqS7Xin0">https://www.steven-obrien.net/</a> -------------------------- Bright New Morning - Steven O'Brien
(Used for free under a Creative Commons Attribution 4.0 License: <a href="https://protect-us.mimecast.com/s/FOoyCv2rxWt4mR9fX52Pt">https://creativecommons.org/licenses/by/4.0/</a>)

Hot Topics in CGT with WIRED's Emily Mullin: Annual Meeting Preview

In 1 playlist(s)

ASGCT Podcast Network

Social links

Follow podcast

Recent clips